Eleftha 150mg Injection
Marketer
Intas Pharmaceuticals Ltd
Salt Composition
Trastuzumab (150mg)
Overview Eleftha 150mg Injection
Oncaspar 150mg Injection treats breast and gastric cancers by targeting and destroying HER2-positive cancer cells. Administered intravenously by a healthcare professional, the dosage and frequency are determined by your physician based on your individual needs and may vary. Strictly adhere to your prescribed regimen; incorrect usage or overdose can lead to severe adverse reactions. Therapeutic effects may not be immediately apparent, requiring several weeks or months; discontinue only under medical supervision. Common side effects encompass nausea, headache, skin rash, sleep disturbances, and increased infection risk. This medication can lower blood cell counts, heightening infection vulnerability, necessitating regular blood tests to monitor blood cell levels, cardiac function, liver health, and uric acid. Report immediately any shortness of breath, cough, chills, or limb swelling. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This injection is contraindicated during pregnancy and lactation; reliable contraception for both partners is crucial throughout treatment.
Primary Ingredients of Eleftha 150mg Injection
No information provided. Please provide the text you wish me to rephrase.
Uses of Eleftha 150mg Injection
Cancers affecting the breast and stomach.
Major Benefits of Eleftha 150mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Eleftha 150mg Injection:
- Anemia (low number of red blood cells)
- Chills
- Common cold
- Cough
- Decreased blood cells (red cells, white cells, and platelets)
- Diarrhea
- Fatigue
- Fever
- Headache
- Heart failure
- Infection
- Insomnia (difficulty in sleeping)
- Mucosal inflammation
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Taste change
- Upper respiratory tract infection
- Weight loss
How to use Eleftha 150mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Eleftha 150mg Injection works:
Oncaspar, a 150mg injectable monoclonal antibody (IgG1), targets HER2 receptors—proteins driving excessive growth in breast and gastric cancers. By binding to HER2, it directly eliminates cancer cells and concurrently blocks the activation of several oncogenic downstream signaling cascades.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of Eleftha 150mg Injection and alcohol may result in pronounced somnolence.
PregnancyCONSULT YOUR DOCTOR
Administering Eleftha 150mg Injection during pregnancy poses a confirmed risk to the fetus and is therefore contraindicated. Nevertheless, a physician might exceptionally prescribe it in critical circumstances where the potential advantages outweigh the inherent dangers. Seek medical advice before use.
Breast feedingCONSULT YOUR DOCTOR
Administering Eleftha 150mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Eleftha 150mg Injection on driving ability is undetermined. Refrain from driving if any symptoms impairing concentration or reaction time are present.
KidneySAFE IF PRESCRIBED
For individuals with kidney impairment, the use of Eleftha 150mg Injection appears to pose minimal risk. Current evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of Eleftha 150mg Injection to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Eleftha 150mg Injection :
Should you forget a scheduled dose of the Eleftha 150mg Injection, seek advice from your physician.
Facts to Know About Eleftha 150mg Injection
| Label | Value |
|---|---|
| Chemical Category | Monoclonal antibody |
| Developing Habits | No. |
| Type of Therapy | Cancer Medications |
| Actions | Monoclonal Antibody HER2/neu (ErbB2) Inhibitor |
3,018 People bought this recently